These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16557046)

  • 1. Clinical trial report stirs debate.
    Magee G; Ovington LG
    Adv Skin Wound Care; 2006 Mar; 19(2):64; author reply 64, 67. PubMed ID: 16557046
    [No Abstract]   [Full Text] [Related]  

  • 2. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
    Armstrong DG
    Indian J Med Sci; 2007 Jun; 61(6):324-5. PubMed ID: 17558094
    [No Abstract]   [Full Text] [Related]  

  • 3. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N; Maltezos E
    Clin Interv Aging; 2008; 3(2):233-40. PubMed ID: 18686746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
    Fruhstorfer B
    Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of Regranex gel for diabetic foot ulcers.
    Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
    Landsman A; Agnew P; Parish L; Joseph R; Galiano RD
    J Am Podiatr Med Assoc; 2010; 100(3):155-60. PubMed ID: 20479444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL
    Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U; Willis M; Odegaard K; Apelqvist J
    Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study.
    Purandare H; Supe A
    Indian J Med Sci; 2007 Jun; 61(6):347-55. PubMed ID: 17558098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.
    Papanas N; Maltezos E
    Drug Saf; 2010 Jun; 33(6):455-61. PubMed ID: 20486728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK; Embil JM
    Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers.
    Niezgoda JA; Van Gils CC; Frykberg RG; Hodde JP
    Adv Skin Wound Care; 2005 Jun; 18(5 Pt 1):258-66. PubMed ID: 15942317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
    Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS
    J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ
    Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ; Smiell JM; Su Y
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
    Ladin D
    Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
    Lantis JC; Boone D; Gendics C; Todd G
    Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.